杨娩玲, 程玉森, 宋乐天, 叶冰, 高升华, 刘新泳, 展鹏. SARS-CoV-2主蛋白酶抑制剂的研究进展J. 药学学报, 2023, 58(9): 2581-2600. DOI: 10.16438/j.0513-4870.2022-1364
引用本文: 杨娩玲, 程玉森, 宋乐天, 叶冰, 高升华, 刘新泳, 展鹏. SARS-CoV-2主蛋白酶抑制剂的研究进展J. 药学学报, 2023, 58(9): 2581-2600. DOI: 10.16438/j.0513-4870.2022-1364
YANG Mian-ling, CHENG Yu-sen, SONG Le-tian, YE Bing, GAO Sheng-hua, LIU Xin-yong, ZHAN Peng. Research progress of SARS-CoV-2 main protease inhibitorsJ. Acta Pharmaceutica Sinica, 2023, 58(9): 2581-2600. DOI: 10.16438/j.0513-4870.2022-1364
Citation: YANG Mian-ling, CHENG Yu-sen, SONG Le-tian, YE Bing, GAO Sheng-hua, LIU Xin-yong, ZHAN Peng. Research progress of SARS-CoV-2 main protease inhibitorsJ. Acta Pharmaceutica Sinica, 2023, 58(9): 2581-2600. DOI: 10.16438/j.0513-4870.2022-1364

SARS-CoV-2主蛋白酶抑制剂的研究进展

Research progress of SARS-CoV-2 main protease inhibitors

  • 摘要: 主蛋白酶(main protease, Mpro) 作为冠状病毒种间相似性极高的共有蛋白酶, 且高度保守, 是病毒复制过程中不可或缺的蛋白水解酶, 因此是抗SARS-CoV-2药物设计的重要靶标。本文针对新型冠状病毒主蛋白酶抑制剂进行全面综述, 涵盖化学结构、抗病毒活性与成药性、结合模式与构效关系等。

     

    Abstract: As a common protease with high similarity among coronavirus species, the main protease (Mpro) of SARS-CoV-2 is responsible for the catalytic hydrolysis of viral precursor proteins into functional proteins, which is essential for coronavirus replication and is one of the ideal targets for the development of broad-spectrum antiviral drugs. This paper reviews the main protease inhibitors of SARS-CoV-2, including their molecular structures, potencies and drug-like profiles, binding modes and structure-activity relationships, etc.

     

/

返回文章
返回